SK282024B6 - Farmaceutický prípravok na inhibíciu adhézie živočíšnych buniek a použitie cyklopeptidov na výrobu liečiva - Google Patents
Farmaceutický prípravok na inhibíciu adhézie živočíšnych buniek a použitie cyklopeptidov na výrobu liečiva Download PDFInfo
- Publication number
- SK282024B6 SK282024B6 SK706-93A SK70693A SK282024B6 SK 282024 B6 SK282024 B6 SK 282024B6 SK 70693 A SK70693 A SK 70693A SK 282024 B6 SK282024 B6 SK 282024B6
- Authority
- SK
- Slovakia
- Prior art keywords
- gly
- phe
- asp
- arg
- cyclo
- Prior art date
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title claims abstract description 19
- 102000001189 Cyclic Peptides Human genes 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims description 12
- 210000004102 animal cell Anatomy 0.000 title claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 230000005764 inhibitory process Effects 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 230000021164 cell adhesion Effects 0.000 claims abstract description 5
- 108010028542 cyclic(arginyl-glycyl-aspartyl-phenylalanyl-leucyl-glycyl) Proteins 0.000 claims abstract description 5
- 108010050963 cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl) Proteins 0.000 claims abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 235000012222 talc Nutrition 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- -1 alkylene glycols Chemical class 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 150000003938 benzyl alcohols Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 210000002997 osteoclast Anatomy 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 2
- YYQUWEHEBOMRPH-NYUBLWNDSA-N 2-[(2s,5r,8s,11s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 YYQUWEHEBOMRPH-NYUBLWNDSA-N 0.000 abstract 1
- OJOVBVONXDWCFW-CBHOWOPOSA-N 2-[(2s,5r,8s,11s,14s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-14-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 OJOVBVONXDWCFW-CBHOWOPOSA-N 0.000 abstract 1
- 108010083321 cyclic(arginyl-alanyl-aspartyl-phenylalanyl-valyl) Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000019997 adhesion receptor Human genes 0.000 description 3
- 108010013985 adhesion receptor Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010265 fast atom bombardment Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000911790 Homo sapiens Sister chromatid cohesion protein DCC1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 102100027040 Sister chromatid cohesion protein DCC1 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90936792A | 1992-07-06 | 1992-07-06 | |
| US2202493A | 1993-02-24 | 1993-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK70693A3 SK70693A3 (en) | 1994-02-02 |
| SK282024B6 true SK282024B6 (sk) | 2001-10-08 |
Family
ID=26695386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK706-93A SK282024B6 (sk) | 1992-07-06 | 1993-07-06 | Farmaceutický prípravok na inhibíciu adhézie živočíšnych buniek a použitie cyklopeptidov na výrobu liečiva |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5866540A (fr) |
| EP (1) | EP0578083B1 (fr) |
| JP (2) | JP3803392B2 (fr) |
| KR (1) | KR100261898B1 (fr) |
| CN (1) | CN1065438C (fr) |
| AT (1) | ATE178491T1 (fr) |
| AU (2) | AU675946B2 (fr) |
| CA (1) | CA2099541C (fr) |
| CZ (1) | CZ283744B6 (fr) |
| DE (1) | DE69324305T2 (fr) |
| DK (1) | DK0578083T3 (fr) |
| ES (1) | ES2131542T3 (fr) |
| HU (1) | HU212572B (fr) |
| MX (1) | MX9304035A (fr) |
| NO (1) | NO307985B1 (fr) |
| PL (1) | PL173785B1 (fr) |
| SK (1) | SK282024B6 (fr) |
| TW (1) | TW393319B (fr) |
| UA (1) | UA43823C2 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
| DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| DE4415310A1 (de) * | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
| US6056958A (en) * | 1994-12-09 | 2000-05-02 | Dupont Pharmaceuticals | Method of treatment of arterial and venous thromboembolic disorders |
| US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
| DE4444260A1 (de) * | 1994-12-13 | 1996-06-20 | Hoechst Ag | Cyclohexapeptide und deren Mischungen, Verfahren zur Herstellung sowie deren Verwendung |
| US5767071A (en) * | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US5780426A (en) * | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| HUP9802675A3 (en) * | 1995-08-14 | 2000-09-28 | Scripps Research Inst | Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis |
| US7053041B1 (en) * | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
| US5817750A (en) * | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
| US6080719A (en) * | 1996-02-23 | 2000-06-27 | Hoechst Aktiengesellschaft | Cyclohexapeptides and their mixtures, a process for preparing them, and their use |
| DE19613933A1 (de) * | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| AU733303C (en) | 1996-05-31 | 2002-08-08 | Scripps Research Institute, The | Methods and compositions useful for inhibition of angiogenesis |
| US6245809B1 (en) | 1996-12-09 | 2001-06-12 | Cor Therapeutics Inc. | Integrin antagonists |
| DE19728524A1 (de) * | 1997-07-04 | 1999-01-07 | Merck Patent Gmbh | Cyclische Azapeptide |
| DE19736772A1 (de) * | 1997-08-23 | 1999-02-25 | Merck Patent Gmbh | Cyclopeptidderivate |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| WO1999065944A1 (fr) * | 1998-06-15 | 1999-12-23 | Ixsys Incorporated | INHIBITEURS PEPTIDIQUES DE αVβ3 ET αVβ¿5? |
| AU756916B2 (en) * | 1998-11-12 | 2003-01-23 | Jcr Pharmaceuticals Co., Ltd. | Modulation of cell proliferative disorders by cyclic RGD |
| UA71608C2 (en) * | 1999-03-11 | 2004-12-15 | Merck Patent Gmbh | A method for producing the cyclic pentapeptide |
| PT1272507E (pt) | 2000-04-12 | 2005-11-30 | Amersham Health As | Derivados de peptidos para ligacao a integrina |
| NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
| US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
| US20030129223A1 (en) * | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
| US20030082103A1 (en) * | 2000-10-11 | 2003-05-01 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| AU3840802A (en) | 2000-11-01 | 2002-06-03 | Merck Patent Gmbh | Methods and compositions for the treatment of diseases of the eye |
| UA75898C2 (en) * | 2000-11-14 | 2006-06-15 | Merck Patent Gmbh | Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors |
| JP4510444B2 (ja) | 2001-07-10 | 2010-07-21 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | ペプチドベースの化合物 |
| US7597907B2 (en) * | 2004-11-05 | 2009-10-06 | Trustees Of The University Of Pennsylvania | Antioxidant polymer nanocarriers for use in preventing oxidative injury |
| US7605056B2 (en) | 2005-05-31 | 2009-10-20 | Semiconductor Energy Laboratory Co., Ltd. | Method of manufacturing a semiconductor device including separation by physical force |
| US7927629B2 (en) * | 2007-10-27 | 2011-04-19 | The Trustees Of The University Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
| US8568786B2 (en) * | 2007-10-27 | 2013-10-29 | The Trustees Of The Universtiy Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
| EP2259768B1 (fr) | 2008-04-08 | 2019-05-22 | Merck Patent GmbH | Compositions contenant des peptides cycliques et leurs procédés d utilisation |
| WO2010075058A1 (fr) | 2008-12-23 | 2010-07-01 | Ge Healthcare Limited | Application d'un composé basé sur le peptide 99mtc à l'imagerie de la moelle osseuse |
| EA201300145A1 (ru) * | 2010-07-16 | 2013-12-30 | Мерк Патент Гмбх | Пептид для применения в лечении рака молочной железы и/или метастазов в кости |
| NZ706356A (en) * | 2012-09-06 | 2018-02-23 | Mcpharma Biotech Inc | Treatment of diarrhea and post-weaning diarrhea with resistant potato starch |
| US11001609B2 (en) | 2017-04-24 | 2021-05-11 | The Regents Of The University Of California | Cell permeable cyclic peptide scaffolds |
| EP3684785B1 (fr) * | 2017-09-19 | 2024-10-02 | Technische Universität München | Peptides cycliques n-méthylés et promédicaments de ceux-ci |
| KR102213196B1 (ko) * | 2018-05-08 | 2021-02-05 | 주식회사 메디폴리머 | 클릭화학 반응을 통해 필러 또는 약물전달체로 사용하기 위한 주사제형 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2945680B2 (ja) * | 1988-09-09 | 1999-09-06 | 旭硝子株式会社 | ペプチド誘導体およびその用途 |
| EP0410537A1 (fr) * | 1989-07-28 | 1991-01-30 | Merck & Co. Inc. | Antagonistes pour le récepteur du fibrinogène |
| ATE155482T1 (de) * | 1990-04-06 | 1997-08-15 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5192746A (en) * | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
-
1993
- 1993-06-18 UA UA93002630A patent/UA43823C2/uk unknown
- 1993-06-24 JP JP15346293A patent/JP3803392B2/ja not_active Expired - Lifetime
- 1993-06-26 AT AT93110232T patent/ATE178491T1/de active
- 1993-06-26 DE DE69324305T patent/DE69324305T2/de not_active Expired - Lifetime
- 1993-06-26 ES ES93110232T patent/ES2131542T3/es not_active Expired - Lifetime
- 1993-06-26 DK DK93110232T patent/DK0578083T3/da active
- 1993-06-26 EP EP93110232A patent/EP0578083B1/fr not_active Expired - Lifetime
- 1993-06-30 CZ CZ931315A patent/CZ283744B6/cs not_active IP Right Cessation
- 1993-07-02 CA CA002099541A patent/CA2099541C/fr not_active Expired - Lifetime
- 1993-07-05 PL PL93299559A patent/PL173785B1/pl unknown
- 1993-07-05 NO NO932439A patent/NO307985B1/no not_active IP Right Cessation
- 1993-07-05 KR KR1019930012550A patent/KR100261898B1/ko not_active IP Right Cessation
- 1993-07-05 HU HU9301950A patent/HU212572B/hu unknown
- 1993-07-05 MX MX9304035A patent/MX9304035A/es unknown
- 1993-07-06 CN CN93108015A patent/CN1065438C/zh not_active Expired - Lifetime
- 1993-07-06 SK SK706-93A patent/SK282024B6/sk not_active IP Right Cessation
- 1993-07-06 AU AU41796/93A patent/AU675946B2/en not_active Expired
- 1993-08-18 TW TW082106697A patent/TW393319B/zh not_active IP Right Cessation
-
1995
- 1995-01-04 US US08/368,760 patent/US5866540A/en not_active Expired - Lifetime
-
1997
- 1997-02-13 AU AU12687/97A patent/AU1268797A/en not_active Abandoned
-
2004
- 2004-05-06 JP JP2004137652A patent/JP4192114B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282024B6 (sk) | Farmaceutický prípravok na inhibíciu adhézie živočíšnych buniek a použitie cyklopeptidov na výrobu liečiva | |
| CA2078347C (fr) | Utilisation de composes contenant du cuivre (ii) pour accelerer la cicatrisation | |
| US4431644A (en) | Antihypertensive agents | |
| US6218417B1 (en) | Ace-inhibitor nitric salts | |
| CA2338524A1 (fr) | Inhibiteurs d'urokinase et de la formation de vaisseaux sanguins | |
| CZ249997A3 (en) | Novel inhibitors of farnesyl transferase, process of their preparation and pharmaceutical compositions containing such inhibitors | |
| HU221092B1 (en) | Compounds with growth hormone releasing properties | |
| KR19990063958A (ko) | 지혈성 디펩티드의 약학 조성물 및 이의 사용방법 | |
| HU228296B1 (en) | Compositions comprising antifungal agent and acetate buffer and their use | |
| CN109232716A (zh) | 多肽和多肽相关化合物的高穿透力前药组合物 | |
| EP0333071A2 (fr) | Polypeptides, méthodes pour leur préparation, les compositions pharmaceutiques les contenant et leur emploi | |
| US6228841B1 (en) | Peptide derivatives | |
| JPS60233097A (ja) | アミノチオールジペプチド類 | |
| EP0850950A1 (fr) | Derives peptidiques | |
| RU2116081C1 (ru) | Циклические ингибиторы адгезии | |
| HUT66469A (en) | Linear peptides | |
| IE42249B1 (en) | Octapeptide derivatives having an oxygen or sulfur containing moiety in the c-terminal position | |
| CA2405724C (fr) | Analogues de la substance p destines au traitement du cancer | |
| JP4601118B2 (ja) | 炎症性疾患治療剤 | |
| NZ279012A (en) | Condensed benzazepine derivatives and medicaments | |
| KR20220102128A (ko) | 신규 그렐린 유사체 및 이를 함유하는 아밀로이드 베타 응집 관련 질환의 예방 또는 치료용 약학 조성물 | |
| CZ9896A3 (en) | Peptide suppressing oxytocin activity | |
| JP2006516980A (ja) | 骨関節症の治療へのブラジキニン−ｂ２受容体拮抗薬の使用 | |
| JPH11322778A (ja) | ５―デオキシ―５―アルカノイルアミノ―β―Ｄ―アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20130706 |